Natalia Andrea Godoy, Jan Gallastegui, Gabriela Velásquez, Stefanie Teuber, Sebastian Brauchi, John Quiroga, Pablo Alarcón, Gabriel Moran, María Angélica Hidalgo, Juan Hancke, Rafael Agustín Burgos
Lameness in dairy cattle, driven by joint inflammation, involves fibroblast-like synoviocytes (FLS) that produce inflammatory mediators and reactive oxygen species (ROS). Tumor necrosis factor alpha (TNF-α) has been proposed as an early systemic inflammatory marker that precedes and accompanies the development of lameness in transition cows. TNF-α signaling promotes ROS production and amplifies the inflammatory response. However, the role of mitochondrial ROS (mtROS) in regulating pro-inflammatory gene expression, particularly in bovine joint inflammation, remains to be elucidated. In this study, we investigated the role of mtROS in TNF-α-stimulated bovine FLS. Using mitochondrial complex inhibitors, complexes I and III were identified as major contributors to mtROS generation. Antioxidants, such as N-acetyl-L-cysteine (NAC) and Mito-Tempo, suppress TNF-α-induced expression of IL-6, IL-8, and IL-1β, with NAC showing broader efficacy in inhibiting COX-2 expression, implicating both cytosolic and mitochondrial ROS in the inflammatory response. TNF-α increased the lactate/pyruvate ratio and the uptake of the fluorescent D-glucose analog 2-[N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino]-2-deoxy-D-glucose (2-NBDG), suggesting an increase in glucose metabolism and a shift toward aerobic glycolysis. TNF-α-induced NOX2 expression was reduced by NAC and Mito-Tempo, thereby linking cytosolic ROS to inflammatory amplification. Mitochondrial networks dynamically shifted from a "networked" to "fragmented" phenotype after TNF-α exposure, accompanied by transient depolarization. Computational classification (UMAP/K-means) confirmed the morphological alterations. These findings demonstrate that mtROS and metabolic rewiring synergistically drive bovine synovial inflammation, highlighting mitochondrial dysfunction as a potential therapeutic target for joint inflammation-associated lameness.